The Effect of Escitalopram on Exacerbation Rates and Quality of Life in Patients With Anxiety Associated With Severe COPD

Trial Profile

The Effect of Escitalopram on Exacerbation Rates and Quality of Life in Patients With Anxiety Associated With Severe COPD

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Anxiety
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 22 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 22 Mar 2015 Planned initiation date changed from 1 Feb 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top